title: Inhibition of ovulation by low-dose mifepristone (RU 486).
abstract: Mifepristone (RU 486) is a potent antigestagen and antiglucocorticoid which when given at a dose of 25-600 mg disrupts folliculogenesis, inhibits ovulation and induces menses in healthy women. This study reports the effects of much lower doses of mifepristone than used previously, given for the duration of a complete menstrual cycle. Healthy female volunteers (n = 11) with regular menstrual cycles were given mifepristone at a daily dose of 5 mg (n = 6) or 2 mg (n = 5) for 30 days, beginning immediately after an ovulatory placebo cycle. Mifepristone prevented menstruation for the duration of the treatment period, with recurrence of menses 15-29 days after replacement of mifepristone with placebo. Daily mifepristone given in either 5 mg or 2 mg doses inhibited ovulation, as indicated by the lack of a rise in urinary pregnanediol excretion. The excretion of oestrone glucuronide in urine rose during treatment, suggesting ovarian follicular development. Inhibition of ovulation appeared to result from a failure of the positive feedback effect of oestradiol on the hypothalamo-pituitary axis, as no surges of luteinizing hormone were seen despite pre-ovulatory levels of oestrone glucuronide being measured during exposure to mifepristone. The cycle immediately following treatment was shorter than the pre-treatment cycle, with lower peak levels of pregnanediol glucuronide, suggesting an inadequate luteal phase. Recovery from the effects of mifepristone treatment was more rapid after 2 mg than after 5 mg and one subject conceived in the immediate post-treatment phase, indicating adequate ovulation and luteinization.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Obstetrics and Gynecology, University of Edinburgh, UK.
authors.forename: W L
authors.initials: WL
authors.lastname: Ledger
authors.forename: V M
authors.initials: VM
authors.lastname: Sweeting
authors.forename: H
authors.initials: H
authors.lastname: Hillier
authors.forename: D T
authors.initials: DT
authors.lastname: Baird
mesh_terms: D000328:Adult; D004966:Estrogens, Conjugated (USP) / Q000652:urine; D004970:Estrone / Q000031:analogs & derivatives / Q000652:urine; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000652:urine; D015735:Mifepristone / Q000008:administration & dosage*; D010060:Ovulation / Q000187:drug effects*; D010907:Pituitary Hormones / Q000652:urine*; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011276:Pregnanediol / Q000031:analogs & derivatives / Q000652:urine; D013256:Steroids / Q000652:urine*
chemical_list: D004966:Estrogens, Conjugated (USP); D010907:Pituitary Hormones; D013256:Steroids; C022270:pregnanediol-3 alpha-glucuronide; C015856:estrone-3-glucuronide; D004970:Estrone; D015735:Mifepristone; D007986:Luteinizing Hormone; D011276:Pregnanediol